 "Jubilant, IDRI extend research for TB drug discovery")
Today is the World Tuberculosis day, designated to build public awareness about the disease.
Jubilant Chemsys offers drug discovery research services on full time equivalent and fees-for-services basis, a company statement said here.
More From This Section
With this association, Jubilant will continue to provide chemistry and medicinal chemistry support to IDRI. The company is also evaluating further liasioning with IDRI in key functional areas like computational chemistry and Drug Metabolism and Pharmacokinetics (DMPK) services.
Jubilant Chemsys, under the terms of agreement, so far had been offering philanthropic support and expertise in synthesis of NCEs to support the early research in TB.
"Jubilant has extended the partnership with IDRI in identifying and discovering novel chemical entities in the area of tuberculosis. The collaboration is leveraging our chemistry talent and our experience in anti-bacterial research," Jubilant Drug Discovery Services president Dr Subir Basak said.
The research outcome will address the current unmet medical need in the field of TB therapy - a growing concern in under developed and developing economies, including India, Basak said.
"We have been impressed with the commitment and engagement from Jubilant Chemsys in support of TB drug discovery over the past few years. We are excited to expand our efforts with them to access additional synthetic and medicinal chemistry capabilities. This will take us another step closer to our goal of developing much-needed new drugs to combat tuberculosis," IDRI vice president of drug discovery, Tanya Parish said.
IDRI is a founding member of both the LTI and the TB Drug Accelerator, a partnership funded by the Bill & Melinda Gates Foundation that targets the discovery of new TB drugs by collaborating on early-stage research.